The Abiraterone 250 mg refers on this website to a product containing 250 mg of abiraterone acetate in an oral tablet.
Product identity
| Characteristic | Information |
|---|---|
| Product | Abiraterone 250 mg |
| Active ingredient | Abiraterone acetate |
| Strength | 250 mg |
| Dosage form | Tablet |
| Route | Oral |
| Drug class | CYP17 inhibitor |
| Therapeutic area | Prostate cancer |
| Reference product | Zytiga |
| Specific manufacturer | Hikma Pharmaceuticals |
| Product authorization | Prescription medicine |
Therapeutic context
Abiraterone acetate is used with prednisone for specified metastatic prostate cancer settings. Current U.S. labeling includes metastatic CRPC and metastatic high-risk CSPC.
Administration
The medicine is taken once daily on an empty stomach according to current U.S. labeling. A 1,000 mg regimen corresponds to four 250 mg tablets when that formulation is used.
Reference product
Zytiga is the reference medicine containing abiraterone acetate. Authorized generic products can have different manufacturers and product presentations while remaining subject to applicable regulatory requirements.
Safety
Important risks include hypertension, hypokalemia, fluid retention, hepatotoxicity and adrenocortical insufficiency.
Verification
The actual manufacturer and authorization status should be checked against the physical package and official regulatory documentation.